Cyclacel Pharmaceuticals - CYCC Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cyclacel Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CYCC shares.
View CYCC analyst ratings or view top-rated stocks.

2 analysts have issued 1-year target prices for Cyclacel Pharmaceuticals' stock. Their CYCC share price forecasts range from $8.00 to $8.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 1,302.3% from the stock's current price.
View analysts price targets for CYCC or view top-rated stocks among Wall Street analysts.

Cyclacel Pharmaceuticals' stock was trading at $0.6670 at the start of the year. Since then, CYCC shares have decreased by 14.5% and is now trading at $0.5705.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 10th 2023.
View our CYCC earnings forecast.

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) issued its earnings results on Monday, March, 6th. The biotechnology company reported ($0.60) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.48) by $0.12.

Shares of Cyclacel Pharmaceuticals reverse split before market open on Wednesday, April 15th 2020. The 1-20 reverse split was announced on Tuesday, April 14th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 14th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

1 employees have rated Cyclacel Pharmaceuticals Chief Executive Officer Spiro Rombotis on Glassdoor.com. Spiro Rombotis has an approval rating of 100% among the company's employees. This puts Spiro Rombotis in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cyclacel Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), Vaxart (VXRT), NVIDIA (NVDA), Novavax (NVAX), Gilead Sciences (GILD), Heat Biologics (HTBX), McEwen Mining (MUX) and Tesla (TSLA).

Cyclacel Pharmaceuticals trades on the NASDAQ under the ticker symbol "CYCC."

Cyclacel Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include Schonfeld Strategic Advisors LLC (6.14%), Millennium Management LLC (1.66%) and HRT Financial LP (0.33%). Insiders that own company stock include Sam L Barker and Spiro George Rombotis.
View institutional ownership trends.

Shares of CYCC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYCC stock can currently be purchased for approximately $0.57.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) has a market capitalization of $7.15 million. The biotechnology company earns $-21,200,000.00 in net income (profit) each year or ($1.90) on an earnings per share basis.

The company employs 2,018 workers across the globe.

Cyclacel Pharmaceuticals' mailing address is 200 CONNELL DRIVE SUITE 1500, BERKELEY HEIGHTS NJ, 07922. The official website for the company is www.cyclacel.com. The biotechnology company can be reached via phone at (908) 517-7330, via email at ir@cyclacel.com, or via fax at 866-271-3466.